AXIM BIOTECHNOLOGIES, INC.
AXIM · OTCMCIK 1514946fmd_0FBEJCQRRBM3K4VWEZEZJ4TCCK制造业 · 医药制剂模板: 标准
覆盖范围: 2011年1月01日 至 2024年6月30日，共 54 个期间
| 项目 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 营业成本 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Operations and maintenance | – | – | – | – | – | – | – | – | – | – |
| 毛利润 | 0 | (0) | (0) | 0 | 0 | 0 | 0 | – | – | – |
| 研发费用 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| 销售、一般及管理费用 | 1 | 9 | 3 | – | – | – | – | 6 | 4 | 2 |
| 营业费用合计 | 1 | 10 | 4 | 3 | 5 | 3 | 5 | 14 | 5 | 3 |
| 营业利润 | (1) | (10) | (4) | (3) | (5) | (3) | (5) | (14) | (5) | (3) |
| 非利息支出 | – | 0 | 0 | – | – | – | – | – | 0 | 0 |
| 利息费用 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 利息及投资收益 | – | – | 0 | 0 | 0 | – | 0 | 0 | – | – |
| 其他营业外收入（支出） | 0 | 0 | (2) | (1) | (2) | 0 | 1 | 2 | 2 | 5 |
| 税前利润 | (1) | (10) | (6) | (4) | (7) | (3) | (6) | (16) | (6) | (8) |
| 所得税费用 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 持续经营净利润 | (1) | (10) | (6) | (4) | (7) | (3) | (6) | (16) | 0 | 0 |
| 净利润 | (1) | (10) | (6) | (4) | (7) | (6) | (6) | (16) | (6) | (8) |
| 归属于普通股股东的净利润 | – | – | (7) | (4) | (7) | (6) | (6) | (16) | (6) | – |